UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
 Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): March 04, 2011
IntelGenx Technologies Corp. 
 (Exact name of registrant as specified in its charter)

Delaware	000-31187	87-0638336	
(State or other jurisdiction	(Commission File No.)	(IRS Employer ID)	
of incorporation)	 	 	
6425 Abrams, Ville Saint Laurent, Quebec, H4S 1X9 Canada
(Address of principal executive offices and Zip Code)
(514) 331-7440
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[   ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
 	 	
[   ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
 	 	
[   ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
 	 	
[   ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	

Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Departure of Director
IntelGenx Technologies Corp. ("IntelGenx" or the "Company) today announced that Professor Thomas Kissel has resigned from the Company’s Board of Directors for medical reasons. Professor Kissel has been a Director of IntelGenx since June 2010. There were no disagreements or misunderstandings between Professor Kissel and the Company regarding any matter relating to the Company’s operations, policies or practices. The resignation is effective immediately and the Board of Directors plans to appoint a new director in the near future to fill the position vacated.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits

Exhibit	Description	
 	 	
99.1	Press Release	
INTELGENX TECHNOLOGIES CORP.

Dated: March 4, 2011	By: /s/Horst Zerbe                 	
 	       Horst G. Zerbe	
 	       President and Chief	
 	       Executive Officer	

Exhibit 99.1
IntelGenx Announces Departure of Director
SAINT LAURENT, QUEBEC, March 4, 2011 - IntelGenx Technologies Corp. (TSX-V: IGX) (OTCBB: IGXT) ("IntelGenx") today announced that Professor Thomas Kissel has resigned from the Company’s Board of Directors for medical reasons. Professor Kissel has been a Director of IntelGenx since June 2010. There were no disagreements or misunderstandings between Professor Kissel and the Company regarding any matter relating to the Company’s operations, policies or practices. The resignation is effective immediately and the Board of Directors plans to appoint a new director in the near future to fill the position vacated.
“We very much regret that Tom had to resign from our Board for medical reasons" said Horst G. Zerbe, President and CEO of IntelGenx. “He was a tremendous asset to the Company in the short time that he served on our Board and we wish him a speedy recovery and good health for the future”.
About IntelGenx Corp.:
IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' research and development pipeline includes products for the treatment of pain, hypertension, erectile dysfunction and depressive disorders. More information is available about the company at www.intelgenx.com .
Each of the TSX Venture Exchange and OTC Bulletin Board has neither approved nor disapproved the contents of this press release.
Contacts:
 IntelGenx Corp.
Dr. Horst G. Zerbe
President and CEO
Tel: +1 514-331-7440 (ext. 201)
Fax: +1 514-331-0436
horst@intelgenx.com
www.intelgenx.com